| Gender (Females N (%)) |
16 (94.1) |
| Age at disease onset (years, M, (IQR) |
31(23-42.5) |
| Age at SF sampling (years, M, (IQR) |
57 (48.5-63.2) |
| Disease duration (years, M, (IQR) |
16 (6-34) |
| Active smoking at sampling (N (%)) |
6 (35.3) |
| Organ involvement |
|
| Lupus Nephritis (N (%)) |
3 (17.6) |
| Cutaneous manifestations (N (%)) |
6 (35.3) |
| Neurolupus (N (%)) |
3 (17.6) |
| Serositis (N (%)) |
2 (11.8) |
| Secondary APS (N (%)) |
3 (17.6) |
| Treatment at sampling |
|
| Glucocorticoids (N (%)) |
10 (58.8) |
| Antimalarial (N (%)) |
10 (58.8) |
| Methotrexate (N (%)) |
3 (17.6) |
| Combined therapy# (N (%)) |
6 (35.3) |
| No active treatment (N (%)) |
2 (11.8) |
| Autoantibodies |
|
| ANA (N (%)) |
17 (100) |
| anti-dsDNA (N (%)) |
6 (35.3) |
| RF (N (%)) |
2 (11.8) |
| anti-SSA/SSB (N (%)) |
4 (23.5) |
| anti-RNP (N (%)) |
3 (17.6) |
| anti-PL (N (%)) |
9 (52.9) |